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Nasal intermittent positive pressure ventilation in acute 
exacerbations of chronic obstructive pulmonary 
disease - a preliminary study 
J.H. CONWAY, R.A. HITCHCOCK, R.C. GODFREYAND M.P. CARROLL* 
Respiratory Support Unit, 03, East Wing, Southampton General Hospital, Tremona Road, 
Southampton SO9 4XY, U.K. 
Ten patients (two male) suffering from acute exacerbations of long-standing chronic obstructive pulmonary 
disease and admitted in hypoxic, hypercapnic respiratory failure were treated with Nasal Intermittent Positive 
Pressure Ventilation (NIPPV) plus supplemental oxygen, on a general medical ward. The median (range) pH on 
admission was 7.30 (7.2s7.35) the median age was 67 years (47-77) with an FEV, (percent of predicted) of 30 
(17-39). On admission the median arterial oxygen tension (PaO,) was 4.71 kPa (3.45626) on air, and the carbon 
dioxide tension (PaCO,) was 7.68 kPa (6.85-9.83). With controlled oxygen therapy there was no significant 
improvement in PaO,, but the median PaCO, increased significantly to 9.75 kPa (7.04-l 1.70) (PC 0.05). By 
using NIPPV with supplemental oxygen it was possible to significantly improve the median PaO, to 11.25 kPa 
(6.7CL26.90) (P < 0.01) without worsening PaCO, levels (8.96 kPa; 6.85-l 3.10). NIPPV was applied by a senior, 
respiratory physiotherapist and used intermittently depending on patient tolerance and clinical response. The 
median total time on NIPPV was 27 h, delivered over l-5 days. One patient found the mask difficult to tolerate 
beyond a short period of time. NIPPV was well accepted on a general ward by nursing staff. Three patients later 
died with progressive hypercapnia, despite an initial response; with one of these patients also receiving intubation 
and mechanical ventilation. A further patient also received intubation and mechanical ventilation and was 
eventually discharged. 
NIPPV plus supplemental oxygen offers a method to correct hypoxaemia on a general medical ward without 
worsening hypercapnia for acute on chronic, hypoxic, hypercapnic respiratory failure, and warrants further 
investigation. 
Introduction 
A major clinical problem in acute on chronic, 
hypoxic, hypercapnic, respiratory failure is the 
inability to adequately oxygenate without worsening 
the hypercapnia and therefore incurring the need to 
support ventilation. When such patients are unrespon- 
sive to initial medical therapy one treatment option, 
which has recently been re-evaluated in Edinburgh (1), 
is the use of the respiratory stimulant doxapram with 
all its attendant difficulties and side effects (2,3). 
Should the patient continue to deteriorate, a further 
option is intubation and mechanical ventilation on 
an intensive care unit, which in chronic obstructive 
pulmonary disease (COPD) can be associated with 
difficulties in weaning (4). We were therefore interested 
in a non-invasive method of reversing hypoxia while 
supporting ventilation. 
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Nasal intermittent positive pressure ventilation 
(NIPPV) is established as an effective method of 
managing nocturnal hypoventilation in the treatment 
of patients with ventilatory pump failure e.g. neuro- 
muscular diseases and severe kyphoscoliosis (5-8). In 
one descriptive study from a national centre, the use of 
NIPPV has been described in a variety of respiratory 
conditions and was suggested to prevent formal intuba- 
tion and ventilation in patients with severe respiratory 
failure (9). More recently, an intermittent positive 
pressure device, delivered via a face mask, was shown 
to be capable of partially correcting hypoxaemia over 
45 min in acutely ill patients with COPD (10). The use 
of a facial mask in this study carries with it the disad- 
vantage of being less acceptable to the claustrophobic 
patient; the device was also not commercially available 
and therefore the results difficult to reproduce; and the 
study was based on an intensive care unit in all cases, 
rather than a general medical ward. 
We report the application of a commercially 
available form of NIPPV in the managment of acute 
@ 1993 Baillitre Tindall 
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respiratory failure on a general medical ward in a dis- 
trict general hospital. The group of patients studied 
were admitted, as a medical emergency in respiratory 
failure secondary to an exacerbation of pre-existing 
airway disease, to a general medical ward as is normal 
practice in the U.K. Nasal ventilation was used in 
conjunction with supplemental, controlled oxygen. 
Our objectives, in this open, descriptive trial, were 
firstly to know whether NIPPV plus supplemental 
oxygen could reverse hypoxaemia without worsening 
hypercapnia; secondly we wished to assess the 
feasibility of using NIPPV on a general medical ward. 
Methods 
PATIENTS 
Clinical details of the patients are shown in Table 1. 
Ten patients (two males) were treated with median age 
of 67 years (range 47-77). These patients were the first 
ten, consecutive admissions to fulfil the entry criteria 
of an emergency admission with acute on chronic 
respiratory failure (defined as PaO,<7.5 kPa and 
PaCO,> 6.0 kPa) which was secondary to long- 
standing obstructive pulmonary disease (> 10 yr). 
Patients were excluded from the trial if there were any 
other major system disorders or a past history of 
malignant lesion(s) of the bronchi. Verbal consent 
was obtained from the patients and if that were not 
possible, from the next of kin, with the assurance that 
the patient could be withdrawn from the trial at any 
time if they so wished. This study was approved by the 
Southampton Joint Ethics Committee. 
STUDY DESIGN 
During this open, descriptive trial, all patients 
received ‘conventional’ medical therapy for their 
respiratory failure (physiotherapy, bronchodilators, 
antibiotics, steroids and in some cases doxapram). 
Arterial blood gases were measured on air, after a 
minimum of 30min of controlled oxygen therapy 
(delivered either via a 2428% venturi mask or nasal 
prongs at 1-2lmin-‘) and following a minimum of 
30 min of NIPPV plus supplemental oxygen. Further 
arterial blood gases were taken according to 
clinical necessity. Oxygen saturation was continuously 
monitored by an Ohmeda Biox 3700 pulse oximeter 
(Ohmeda Ltd, Hatfield, Herts, U.K.). 
Constant liaison was maintained between the staff 
on the general medical ward concerned and the 
intensive care unit. Failure of NIPPV was decided on 
clinical grounds. The patient would then be referred to 
the intensive care unit for intubation and mechanical 
ventilation if this was deemed appropriate by all con- 
cerned. The early discussion of all such patients with 
the intensive care unit staff facilitated the referral of 
those who required mechanical ventilation. 
An impression of the ease of application of NIPPV 
by the operator (physiotherapist) and a member of the 
nursing staff was assessed daily. Individual patients 
rated the acceptability of NIPPV on the third day of 
admission or as soon as was practicable. Clinical 
outcome was recorded. 
NIPPV 
All members of staff involved with the trial were 
given the appropriate introduction and training on the 
use of NIPPV. 
NIPPV was delivered via a Brompton Pneupac 
ventilator (Pneupac Ltd., Luton, Bedfordshire, U.K.) 
using a tight-fitting, contoured, nasal mask (Medic- 
Aid Ltd., Pagham, W Sussex, U.K.). This ventilator 
delivers a set volume which is time cycled thus ensuring 
a minimum respiratory rate while allowing the patient 
to trigger ventilation. The following adjustments on 
the Brompton Pneupac are possible: the rate of flow 
(1 s-l) of compressed air delivered during inspiration, 
inspired time (s) (Tr) and expired time (s) (TE). The 
mask was held in place by a head strap. An additional 
chin strap was used when necessary to prevent mouth 
breathing. Nasal discharge was kept to a minimum by 
ephedrine nose drops and pressure sores over the 
bridge of the nose were prevented with Granuflex 
dressing (Squib Surgicare Ltd., Hounslow, Middlesex, 
U.K.). 
APPLICATION OF NIPPV 
This was the responsibility of a senior respiratory 
physiotherapist. The initial settings of the Pneupac 
ventilator were a flow rate of 0.7 1 s-‘, a TI of 1 s and a 
TE of 2 s. These initial settings were then adjusted to 
achieve optimum comfort, whilst at the same time 
optimizing arterial blood gases and oximetry. Supple- 
mental oxygen was in all cases supplied through a port 
in the nasal mask from a wall supply. The appropriate 
flow of oxygen and thus inspired concentration was 
titrated against oxygen saturation (oximetry) and 
arterial blood gases. 
The first ‘session’ lasted approximately 1 h, though 
there was a range of 30 min to 2 h, depending on the 
clinical state of the patient and on patient acceptance. 
Further intermittent NIPPV was delivered with maxi- 
mum time on the ventilator sought but with necessary 
breaks for physiotherapy, nebulizers, meals etc. 
DATA ANALYSIS 
Results were analysed using the Wilcoxon signed 
rank test. Median values with minimum to maximum 
ranges are used to illustrate the spread of data. 
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Admission Admission Inkal ’ b&an Admission Admission Initk ’ kian 
(air) (02) NIPPV (02) NIPPV (02) (air) (02) NIPPV (02) NIPPV (0~) 
Fig. I Arterial blood gases; (a) PaO, and (b) PaCO, for each subject at four time points: on admission on air; on admission 
with 24% fractional inspired oxygen through a face mask or 2 1 min- ’ oxygen through nasal cannulae; following the first session 
of NIPPV with 2 1 mini supplemental oxygen; and the median value for all sessions on NIPPV with supplemental oxygen 
(2 1 min’). The three patients that died (subjects 3,s and 7) are denoted by the closed symbol 0 and the closed star *. The one 
patient that necessitated transfer to intensive care (subject 9) and was later discharged home is denoted by the closed triangle A. 
Visual analogue scales were used as a description of 
acceptance only. 
Results 
Ten patients (two male) with a median age of 
67 years (47-77) were admitted to a medical ward 
at Southampton General Hospital suffering from 
acute infective exacerbations of long-standing airways 
disease. No patient was assessed as having pulmonary 
oedema, and bronchoconstriction was not a major 
complication of their infective exacerbation. All were 
treated with NIPPV plus supplemental oxygen. The 
results of this study will be presented in two ways, 
firstly for the individual response to NIPPV and 
secondly an analysis of the group response. 
INDIVIDUAL RESPONSE 
Table 1 describes the clinical details, arterial blood 
gas tensions and outcome for individual patients. 
Figure 1 depicts the arterial blood gas tensions for the 
individual patients described in Table 1. The blood gas 
tensions presented are those taken on admission on 
air, on oxygen, following the first session on NIPPV 
and also the median values of all samples taken whilst 
on NIPPV. 
On admission, all of the patients were in acute, 
hypoxic, hypercapnic, respiratory failure and pre- 
sented with a history of long-standing COPD. The lack 
of improvement in levels of hypoxaemia following 
conventional oxygen therapy and the increase in 
hypercampnia due to this therapy is shown in Table 
1 and Fig. 1. All arterial blood gases were taken 
following 2 1 min’ oxygen via nasal prongs or 24% 
fractional inspired oxygen via a face mask. 
The main effect of NIPPV with supplemental 
oxygen in this group of patients was an immediate and 
sustained increase in levels of PaO,. In most this was 
not accompanied by a worsening of PaCO,. The mean 
supplemental oxygen concentration used with NIPPV 
was2lmin’. 
Three patients died during the trial (2,5 and 15 days 
after entry). These three patients are represented by the 
symbol * in Fig. 1. 
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Patient 3 received NIPPV for 3 days and died on 
day 5. This patient was well known to the respiratory 
physicians. A sharp decline in lung function and exer- 
cise tolerance had been documented in the preceding 
year. Following the initial session with NIPPV plus 
oxygen his hypoxaemia improved from 4.46 kPa (on 
air) to 12.91 kPa, without a major increase in his 
hypercapnia (PaCO, 9.07 kPa to 9.89 kPa with 
NIPPV). However, his condition deteriorated on day 
3, reflected in the median values for arterial blood 
gases whilst on NIPPV (PaO, remaining high at 11.28 
kPa but the hypercapnia increasing to 12.91 kPa). 
After consultation with the family, active treatment 
was withdrawn on day 4. The patient died on day 5. 
Patient 5 had failed to respond to conventional 
therapy, including i.v. doxapram, before NIPPV was 
commenced (PaO, 4.60 kPa, PaCO, 9.87 kPa) on con- 
trolled oxygen). Despite an initial response to NIPPV 
(PaO, 7.88 kPa, PaCO, 10.18 kPa) this patient 
continued to deteriorate and on day 2 active treatment 
was withdrawn after taking into consideration the pre- 
admission quality of life and since it was judged that 
any further treatment would be ineffective. She died 
the same day. 
Patient 7 was admitted and rapidly deteriorated. 
This patient was unknown to the respiratory phys- 
icians. She failed to respond to conventional therapy 
which included doxapram (PaO, 4.71 kPa, PaCO, 
10.8 1 kPa on controlled oxygen). NIPPV was applied 
with an initial improvement of hypoxaemia. However 
sputum retention became the main management prob- 
lem and for that reason and in view of the severity of 
this patients condition she was transferred to intensive 
care for intubation and mechanical ventilation on day 
2. She died in intensive care on day 15. 
Patient 9 was the youngest of the group. This patient 
is represented by the symbol A in Fig. 1. She too had 
failed to respond to conventional therapy including 
doxapram (PaO, 3.82 kPa, PaCO, 9.92 kPa on 
controlled oxygen). She had responded well to NIPPV 
initially with an improvement in hypoxaemia and a 
decrease in levels of hypercapnia (PaO, 6.11, PaCO, 
6.60). However despite this improvement she appeared 
to be tiring, reflected in the increase in PaCO, to 9.94 
kPa for the median value of blood gases on NIPPV. 
In view of her age (47 years) and the severity of her 
condition she was referred to intensive care for intuba- 
tion and mechanical ventilation on day 2. This lady 
was eventually discharged home and has since had a 
succesful, single lung transplant. 
The three patients who died all responded favourably 
to the initial session of NIPPV but could later be 
distinguished by a relentless and progressive rise in 
PaCO, which was unresponsive to treatment despite 
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Fig. 2 Median (inter-quartile range) arterial blood gases. 
Values shown are: on admission on air, on admission with 
24% fractional inspired oxygen through a face mask or 
2 I min-’ though nasal cannulae, and the median value for all 
sessions on NIPPV with supplemental oxygen (2 1 minm ‘). 
PaO, (-•-), PaCO, (-•-). 
maximization of conventional therapy and NIPPV. 
Patient 9 also showed this progressive rise in PaCO, 
despite a good initial response to NIPPV. These four 
patients (patients 3, 5, 7 and 9) recorded the four 
highest median levels of PaCO, whilst on NIPPV 
(Table 1, Fig. 1). 
Other than the patients described above (patients 3, 
5,7 and 9) two other patients had received doxapram 
unsuccessfully within 24 h prior to starting NIPPV 
(patients 1 and 4). 
All the remaining patients (1, 2, 4, 6, 8 and 10) 
showed an immediate and marked improvement in the 
levels in PaO, following the initial session of NIPPV 
plus supplemental oxygen without an increase in hyper- 
capnia compared with the response to conventional 
oxygen therapy (Table 1, Fig. 1). This improvement 
in hypoxaemia without an increase in the levels 
of hypercapnia was sustained in these patients as 
described in Table 1 by the median of all samples of 
arterial blood gases whilst on NIPPV. These patients 
were all discharged home following a progressive 
recovery. 
GROUP ANALYSIS 
Figure 2 represents the median (interquartile range) 
values of arterial blood gas tensions on admission on 
air, on oxygen and median values of all sessions on 
NIPPV, for all ten patients. 
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The median arterial pH of 7.30 (range 7.20-7.35) on 
admission reflects the acuteness of the admissions, 
and the severity of the respiratory failure is seen in 
the degree of hypoxaemia and hypercapnia (Table 1). 
Analysis of blood gas tensions on admission reveals 
that for the group the median (range) arterial oxygen 
tensions on admission were 4.71 kPa (3.45-6.26) on 
air and 4.60 kPa (3.82-8.28) with controlled oxygen 
therapy; there was no significant difference between 
these two sets of values. The corresponding medians 
(range) for arterial carbon dioxide tensions were 7.68 
kPa (6.85-9.83) with air increasing significantly to 9.75 
kPa (7.04-l 1.70) with controlled oxygen (P < 0.05). 
All of the ten patients demonstrated an improve- 
ment in hypoxaemia after a minimum of 30 min of 
NIPPV plus oxygen compared to controlled oxygen 
alone (in the case of subject 3 the comparison was 
with the arterial oxygen tension whilst breathing air). 
The same comparison was made for carbon dioxide 
tensions and for the group as a whole there were minor 
changes (less than 1 kPa) in the level of hypercapnia 
following the initial session of NIPPV except for cases 
8, 9 and 10 where there was a moderate reduction in 
hypercapnia. 
Statistical analysis of the blood gas tensions following 
the initial session of NIPPV plus supplemental oxygen 
demonstrates this immediate and significant improve- 
ment in arterial hypoxaemia compared to the blood 
gas tensions following controlled oxygen alone; with 
the median value increasing to a PaO, of 9.13 kPa 
(range 6.1 l-24.46) on NIPPV from a PaO, of 4.60 kPa 
(range 3.82-8.28) on controlled oxygen (P<O.Ol). 
There was no significant difference in the levels of 
hypercapnia. 
The overall effect of NIPPV was judged by calculating 
the median of all arterial blood gas tensions whilst on 
NIPPV. Individually it can be seen that the improve- 
ment in hypoxaemia is maintained in all cases. The 
levels of hypercapnia were little changed except for 
the three subjects who later died (patients 3, 5 and 7) 
and for subject 9, where an increase in hypercapnia is 
described. Analysis of the median effect of NIPPV 
compared to controlled oxygen, showed that following 
NIPPV with supplemental oxygen the median arterial 
carbon dioxide tension decreased to 8.96 kPa (6.85- 
13.12) whilst the oxygen tension increased significantly 
to 11.25 kPa (6.70-26.90) (PcO.01). The median total 
time on NIPPV was 27 h (range l&53) over l-5 days. 
The median flow of supplemental oxygen delivered to 
the nasal mask of the NIPPV was 2 1 min-‘. 
Patients 5, 7 and 9 were unable to rate the 
acceptability of NIPPV due to the severity of their 
condition and their transference to the intensive care 
unit. The remaining seven patients found NIPPV to 
be comfortable with a reported improvement in the 
sensation of breathlessness whilst on the NIPPV to 
when off it. Five patients were able to sleep whilst using 
NIPPV whilst for two patients sleep was disturbed. 
One patient with a history of claustrophobia found the 
mask unacceptable beyond short periods of time (1 h 
maximum). 
NIPPV was applied by the operator with moderate 
ease to all patients. The patients were assessed by the 
operator as accepting NIPPV well; with the rating for 
acceptance as increasing daily. Comfort of the patient 
was similarly assessed by a senior nursing staff as good 
with acceptance increasing daily. 
Discussion 
The intention of this open, descriptive study was 
firstly to quantify the effect of NIPPV with supple- 
mental oxygen on hypoxaemia in acute on chronic, 
hypoxic, hypercapnic respiratory failure and secondly 
we wished to assess the feasibility of using NIPPV on a 
general medical ward. In this group of ten patients 
admitted as medical emergencies, conventional oxygen 
therapy had no significant effect on the levels of PaO, 
but was accompanied by a significant (PcO.05) in- 
crease in the levels of hypercapnia. Following the first 
session of NIPPV plus supplemental oxygen (mini- 
mum time of 30min) hypoxaemia was significantly 
improved (P < 0.01) compared with conventional 
oxygen therapy alone. Most importantly, there was 
no significant increase in the levels of hypercapnia 
accompanying the first session of NIPPV. Analysis 
of the levels of hypoxaemia on all occasions whilst 
on NIPPV also showed a significant improvement 
(P<O.Ol). Levels of hypercapnia were not signifi- 
cantly altered. Therefore the main therapeutic 
advantage of using NIPPV, combined with added 
oxygen is the correction of severe hypoxaemia without 
increasing hypercapnia. 
The patients presenting to our study were severely 
unwell. In the U.K. such patients are routinely 
admitted to a medical ward rather than an intensive 
care unit. The purpose of this study was to see if 
NIPPV could be used with success in a ward setting, 
within the present clinical framework. Doxapram is 
used in the U.K. as a respiratory stimulant for extreme 
cases in an attempt to avoid mechanical ventilation (1) 
and was therefore included as a possible, conventional 
therapy. 
The severity and the acute nature of the presentation 
of this group of patients was reflected in the levels of 
hypercapnia, hypoxaemia and acidosis on admission 
(Table 1). There was no correlation between the out- 
come and the degree of airways obstruction. In two 
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patients (patients 3 and 5) the severity of the under- 
lying disease resulted in the withdrawal of active 
management with the subsequent deaths of these two 
patients. In two others (patients 7 and 9) formal 
ventilation on an intensive care unit was considered 
appropriate: of these one died (patient 7) and one was 
eventually discharged home and has subsequently 
been the successful recipient of a single lung transplant 
(patient 9). The approximate incidence of patients 
admitted to our unit and who go on to receive lung 
transplantation is one per year. Therefore this sample 
of patients could be considered atypically severe, and 
does highlight the need for a larger controlled trial. In 
all four cases (patients 3,5,7 and 9) although there was 
an initial response to ventilatory support with NIPPV 
plus oxygen, the underlying pathology was such that 
this form of ventilation was inadequate; this being 
reflected in all four by a relentless rise in the levels of 
hypercapnia which was unresponsive to conventional 
medical therapy of NIPPV. At that point, the decision 
had to be made to refer the patient to the intensive care 
unit or to stop active management. In the two patients 
where active management was withdrawn (on days 4 
and 2 for patient 3 and 5 respectively) NIPPV had 
allowed enough time for the assessment of their respir- 
atory condition and quality of life to be considered. 
NIPPV is not a substitute for mechanical ventilation 
indeed in patients 7 and 9 intubation and mechanical 
ventilation became necessary. It can therefore be 
suggested that nasal ventilation is a useful treatment 
option between conventional oxygen therapy and 
before recourse to intubation and full mechanical 
ventilation on an intensive care unit. Our study further 
suggests that a relentless rise in PaCO, is a sign of 
failure of NIPPV as in other forms of therapy for 
respiratory failure. 
It was possible to use nasal ventilation on a busy 
general medical ward which was ‘on take’ for acute 
medical emergencies. No additional nursing staff were 
needed. The nasal mask was applied by a senior, 
respiratory physiotherapist. Settings on the ventilator 
were aimed at patient acceptability and comfort rather 
than mandatory ventilation levels. Nasal ventilation 
was achieved in this group of acutely ill patients despite 
the presence of distress, and in some, confusion and 
dyspnoea. One factor in the successful treatment of 
such acutely ill patients with NIPPV was the unique 
handling and positioning skills of the respiratory 
physiotherapists. When familiarized with NIPPV, 
most patients were able to tolerate the ventilator 
during sleep. This method of ventilation has the 
advantage that between periods of treatment the 
patient was not immobilized. It is possible for patients 
to eat, receive physiotherapy, use a nebulizer and, were 
possible, to care for themselves. One of the group 
(patient 2) found the mask difficult to tolerate beyond 
a short period of time (1 h maximum), although 
despite this, improvement of her respiratory failure 
occurred. 
An advantage of NIPPV, unlike endo-tracheal 
ventilation, is that paralysing and sedating agents are 
not required to achieve ventilatory assistance; and 
since NIPPV is patient triggered, the intrinsic need and 
drive to breath is not removed. We postulate that this is 
why no patient had problems with weaning. Removal 
of NIPPV did not precipitate an immediate respiratory 
crisis in any individual. Furthermore in no patient was 
there a precipitous rise in PaCO, on NIPPV plus 
oxygen; where there was a rise it occurred slowly and 
accompanied a relentless worsening of the clinical 
state. 
The mechanisms behind the improvements in blood 
gases with NIPPV are probably multiple. NIPPV 
allows the support of ventilation by timed and/or trig- 
gered positive pressure, with the option of delivering 
supplemental oxygen. The marked increase in PaO, 
may therefore be due to a more effective delivery of 
oxygen using this system. A further possible mechanism 
for the raised levels of PaO, found in this study fol- 
lowing NIPPV is an increase in ventilation perfusion 
matching caused by opening of atelectatic areas 
with positive pressure. The potential advantages of 
correcting hypoxaemia are numerous and include 
improvement of mental state, cardiac and renal 
function, tissue perfusion and the ability to over- 
come infection. In contrast, a possible disadvantage 
of the hyperoxic state we achieved is the occurrence 
of ventilation perfusion mismatching as a result of 
reflex, hyperoxic vasodilation in areas of poor or no 
ventilation. 
Another possible advantage of NIPPV is the 
achievement of respiratory muscle rest. In acute 
respiratory failure it is thought that respiratory 
muscles are severely stressed. It is therefore feasible 
that respiratory muscle rest occurs whilst on NIPPV. 
Furthermore, patients were observed to regularize 
their patterns of breathing whilst on the nasal venti- 
lator. The timed, intermittent nature of the ventilation 
very probably acts as a regular stimulus to breath. 
This study has described a possible, new technique 
in the management of acute on chronic respiratory 
failure. However, in this group of patients we cannot 
exclude a delayed benefit of ‘conventional therapy’ to 
explain our findings. It is also necessary to evaluate 
the effect of an improvement in respiratory failure on 
clinical course. To test the hypothesis that NIPPV 
could be advantageous in the management of acute, 
hypoxic, hypercapnic respiratory failure, a controlled, 
394 J. H. Conway et al. 
randomized, three-centre trial comparing NIPPV plus 
conventional treatment, with conventional treatment 
alone, is in progress. The outcome parameters will 
include, length of stay in hospital, admission to ITU 
and eventual outcome. 
We conclude that the use ofNIPPV with supplemental 
oxygen has a potential place in the management of 
hypoxic, hypercapnic, respiratory failure due to acute 
exacerbations of chronic obstructive pulmonary 
disease. Secondly it is possible to use NIPPV on a 
general medical ward if there is a critical group of 
trained staff including senior respiratory physiothera- 
pists, nurses and physicians; with ready access to an 
intensive care unit. 
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